-

05:57:47 PM

ABUS Stock News

ABUS - Arbutus Biopharma Corp

03/16/23 7:30 AM

Nasdaq : ABUS

clinical trial

Arbutus Doses First Subject in Phase 1 Clinical Trial with its Oral RNA Destabilizer, AB-161

Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific

RHEA-AI

neutral

03/14/23 4:05 PM

Nasdaq : ABUS

Arbutus Presents AB-343 Data at the 36th International Conference on Antiviral Research

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage

RHEA-AI

neutral

03/02/23 7:30 AM

Nasdaq : ABUS

earnings

Arbutus Reports Fourth Quarter and Year End 2022 Financial Results and Corporate Update

Significant progress made advancing proprietary programs in chronic HBV and Coronavirus AB-729 data from multiple Phase 2a combination clinical trials expected in 2023 Initial Phase 1 data for oral PD-L1, AB-101, and oral RNA Destabilizer, AB-161, expected in the second half of 2023 Initiate Phase

RHEA-AI

neutral

02/16/23 7:30 AM

Nasdaq : ABUS

conferencesearnings

Arbutus to Report Fourth Quarter and Year End 2022 Financial Results and Provide Corporate Update

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its

RHEA-AI

neutral

02/06/23 7:30 AM

Nasdaq : ABUS

conferences

Arbutus to Participate in Three Upcoming Investor Conferences

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Arbutus management

RHEA-AI

neutral

01/27/23 7:30 AM

Nasdaq : ABUS

management

Arbutus Announces Resignation of Board Member

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that Tram Tran, MD has

RHEA-AI

neutral

01/05/23 7:30 AM

Nasdaq : ABUS

Arbutus Announces 2023 Corporate Objectives and Provides Financial Update

Data from multiple Phase 2a clinical trials combining AB-729 with other compounds expected in 2023 Plans to advance HBV assets, AB-101 and AB-161, and newly nominated coronavirus asset, AB-343, into Phase 1 clinical trials in 2023 Strong financial position; cash runway into Q4 2024 WARMINSTER, Pa.,

RHEA-AI

neutral

12/13/22 7:30 AM

Nasdaq : ABUS

clinical trial

Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company

RHEA-AI

neutral

11/09/22 7:30 AM

Nasdaq : ABUS

earnings

Arbutus Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Financially strong with a projected cash runway into the second quarter of 2024 HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729, our RNAi therapeutic, and NA therapy On-track to achieve multiple additional milestones before year

RHEA-AI

neutral

11/08/22 7:30 AM

Nasdaq : ABUS

conferences

Arbutus to Present at Jefferies London Healthcare Conference

Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Arbutus’

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 Next

ABUS Data

IndustryPharmaceutical Preparation Manufacturing
Websitearbutusbio.com
CeoWilliam Collier
Security nameArbutus Biopharma Corp
Issue typecs
SectorManufacturing
Sic code2834
Employees87
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address701 Veterans Circle
StatePennsylvania
CityWarminster
Zip18974
CountryUS
Phone12674690914

About Arbutus Biopharma Corp

Arbutus Biopharma Corporation is a biopharmaceutical company primarily dedicated to discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection. The Company is advancing multiple drug product candidates that may be combined into a potentially curative regimen for chronic HBV infection. Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).